Category «News»

Pharma CCO: The Next Pharma Services Buy-and-Build Opportunity?

Growing drug-launch complexity, expanding market-access requirements, and increasing demand for outsourced commercialization services are creating an attractive investment opportunity in the pharma CCO market. The pharmaceutical industry is entering a period in which commercialization is becoming increasingly complex. The rise of specialty and orphan drugs, more demanding market-access requirements, growing evidence expectations, and the need …

Sub-Saharan Africa Pharmaceuticals Market Set for Strong Growth as Healthcare Access and Local Drug Manufacturing Expand

Sub-Saharan Africa’s pharmaceutical market is projected to grow from approximately $8 billion in 2025 to $13 billion by 2030, supported by rising healthcare demand, increasing access to medicines and efforts to expand pharmaceutical manufacturing across the region, according to Medi-Tech Insights. The Sub-Saharan Africa pharmaceuticals market is forecast to expand at a 10.2% CAGR from …

Doorstep Treatment Market Size Set to Reach USD 776 Billion by 2035 as Home Healthcare Demand Accelerates

Global Doorstep Treatment Market was valued at USD 425.2 billion in 2025 and is projected to grow at a 6.2% CAGR from 2026 to 2035, supported by rising demand for convenient, technology-enabled healthcare services delivered at home. The healthcare industry is witnessing a continued shift toward decentralized care as patients increasingly seek medical services that …

Forus Raises $150 Million at $3 Billion Valuation as AI Platform Expands Across U.S. Healthcare

Forus Raises $150M at $3B Valuation: AI Healthcare Platform Expands

AI healthcare company Forus has raised $150 million in Series C financing, bringing its valuation to $3 billion as the company expands its artificial intelligence-powered healthcare network designed to help connect physicians, patients, pharmacies, insurers and biopharmaceutical companies. The latest financing marks a significant increase in Forus’ valuation. The company has tripled its valuation in …

Medtronic Reports $9.76 Billion Revenue, Raises FY2027

Medtronic has raised its fiscal 2027 revenue-growth forecast and increased the lower end of its adjusted earnings outlook after reporting strong first-quarter demand across its cardiovascular portfolio. The medical technology company said on September 1 that it now expects organic revenue growth of 7.25% to 7.75%, compared with its previous forecast of 6.75% to 7.25%. …

How Surrogacy Works: 2026 Data, Success Factors, Risks, and Legal Rules

Surrogacy statistics 2026 guide comparing process, costs, laws, success factors, and IVF

Surrogacy can provide a family-building route when pregnancy is impossible, medically unsafe, or biologically unavailable to an intended parent. It may be considered by people with uterine-factor infertility, some cancer survivors, male same-sex couples, single intended fathers, and others after individualized medical and legal review. Accurate information matters because surrogacy combines assisted reproductive technology, pregnancy …

Zydus Lifesciences Profit Drops 36% Despite Revenue Growth

Zydus Lifesciences’ first-quarter net profit declined 35.9% to ₹9.40 billion, despite strong revenue growth. Revenue from operations increased 22% to ₹80.17 billion, supported by India formulations, international markets and consumer wellness. EBITDA fell 7.6%, while the EBITDA margin narrowed sharply to 24.1% from 31.8% a year earlier. India-based Zydus Lifesciences reported a 35.9% decline in …

Peptide CDMO Market Emerges as a Billion-Dollar Manufacturing Opportunity

Peptide CDMO Market Growth and Opportunity

The Peptide CDMO Market is gaining strategic importance as pharmaceutical and biotechnology companies increase their investment in peptide-based therapeutics. Rapid growth in GLP-1 medicines, expanding cardiometabolic pipelines and the development of next-generation peptide drugs are creating substantial demand for specialized manufacturing capacity. According to Medi-Tech Insights, the Peptide CDMO Market is projected to grow at …

Merck lifts 2026 profit outlook as life science, chip demand rises

Germany’s Merck KGaA raised its 2026 profit guidance after second-quarter adjusted earnings exceeded expectations, supported by stronger demand in its Life Science and Electronics businesses and easing currency pressure. The Darmstadt-based science and technology group now expects adjusted earnings before interest, taxes, depreciation and amortisation, or EBITDA, of €5.9 billion to €6.3 billion in 2026. …

FDA Approves First mRNA Flu Vaccine for Adults Aged 50 and Older

Moderna mFlusiva first mRNA flu vaccine approved by FDA

The US Food and Drug Administration has approved Moderna’s mFlusiva, making it the first mRNA-based seasonal influenza vaccine cleared for public use. The vaccine is approved for adults aged 50 years and older and is expected to become available in the United States during the 2026–2027 respiratory virus season. The decision represents an important expansion …